Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-positive Relapsed or Refractory B-cell Malignancies”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Early research (Phase 1)Looking for participantsNCT06047197
What this trial is testing

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-cell Lymphoma
Beijing Yongtai Ruike Biotechnology Company Ltd 25
Testing effectiveness (Phase 2)UnknownNCT02892695
What this trial is testing

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)UnknownNCT04204161
What this trial is testing

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Who this might be right for
Relapsed B-cell Acute Lymphoblastic Leukemia, ChildhoodRefractory B-cell Acute Lymphoblastic Leukemia, ChildhoodRelapsed/Refractory B-cell Lymphoma, Childhood
Shenzhen BinDeBio Ltd. 30
Testing effectiveness (Phase 2)UnknownNCT02851589
What this trial is testing

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Looking for participantsNCT06213636
What this trial is testing

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Who this might be right for
Acute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in RelapseNon-Hodgkin Lymphoma, B-cell+4 more
Essen Biotech 75
Testing effectiveness (Phase 2)Looking for participantsNCT06834529
What this trial is testing

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Who this might be right for
Relapsed or Refractory B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences 20
Early research (Phase 1)UnknownNCT04037566
What this trial is testing

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Who this might be right for
Leukemia Lymphocytic Acute (ALL) in RelapseLeukemia Lymphocytic Acute (All) RefractoryLymphoma, B-Cell+1 more
Xijing Hospital 40
Early research (Phase 1)Temporarily pausedNCT06447987
What this trial is testing

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
City of Hope Medical Center 24
Early research (Phase 1)Ended earlyNCT05336409
What this trial is testing

CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Who this might be right for
R/R CD19-Positive B-Cell MalignanciesIndolent Non-Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Century Therapeutics, Inc. 28
Early research (Phase 1)Looking for participantsNCT06287528
What this trial is testing

19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Philadelphia-Negative ALLPhiladelphia-Positive ALLRelapsed ALL, Adult+3 more
Memorial Sloan Kettering Cancer Center 18
Early research (Phase 1)Active Not RecruitingNCT04007029
What this trial is testing

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic Leukemia+11 more
Jonsson Comprehensive Cancer Center 24
Early research (Phase 1)Study completedNCT02746952
What this trial is testing

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Institut de Recherches Internationales Servier 25
Testing effectiveness (Phase 2)Looking for participantsNCT06533579
What this trial is testing

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc. 32
Testing effectiveness (Phase 2)UnknownNCT02819583
What this trial is testing

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)Looking for participantsNCT07133997
What this trial is testing

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
City of Hope Medical Center 26
Early research (Phase 1)Ended earlyNCT02106091
What this trial is testing

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

Who this might be right for
Relapsed B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma
Affimed GmbH 16
Early research (Phase 1)Study completedNCT03029338
What this trial is testing

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Who this might be right for
Lymphomas Non-Hodgkin's B-CellRelapse
Institute of Hematology & Blood Diseases Hospital, China 20
Early research (Phase 1)Active Not RecruitingNCT07166419
What this trial is testing

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Who this might be right for
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+12 more
Ohio State University Comprehensive Cancer Center
Not applicableUnknownNCT02813837
What this trial is testing

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Who this might be right for
Leukemia, B-CellLymphoma, B-Cell
Innovative Cellular Therapeutics Co., Ltd. 30
Very early researchUnknownNCT06277011
What this trial is testing

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
Anhui Provincial Hospital 18
Next Page
24